Change in prevalence and molecular characteristics of isoniazid-resistant tuberculosis over a 10-year period in China

Change in prevalence and molecular characteristics of isoniazid-resistant tuberculosis over a 10-year period in China

Abstract Background Isoniazid (INH) represents the cornerstone for the treatment of cases infected with Mycobacterium tuberculosis (MTB) strains. Several molecular mechanisms have been shown to be the major causes for INH resistance, while the dynamic change of mutations conferring INH resistance am...

Full description

Bibliographic Details
Main Authors:	Fengmin Huo, Jie Lu, Zhaojing Zong, Wei Jing, Jin Shi, Yifeng Ma, Lingling Dong, Liping Zhao, Yufeng Wang, Hairong Huang, Yu Pang
Format:	Article
Language:	English
Published:	BMC 2019-08-01
Series:	BMC Infectious Diseases
Subjects:	Tuberculosis Isoniazid Drug resistance inhA Protionamide
Online Access:	http://link.springer.com/article/10.1186/s12879-019-4333-4

Similar Items

Integrative utility of long read sequencing-based whole genome analysis and phenotypic assay on differentiating isoniazid-resistant signature of Mycobacterium tuberculosis
by: Ming-Chih Yu, et al.
Published: (2021-12-01)

In vitro modeling of isoniazid resistance mechanisms in Mycobacterium tuberculosis H37Rv
by: Thanadon Dokrungkoon, et al.
Published: (2023-07-01)

Computational approach to understanding the mechanism of action of isoniazid, an anti-TB drug
by: Lingaraja Jena, et al.
Published: (2014-01-01)

Isoniazid resistance-conferring mutations are associated with highly variable phenotypic resistance
by: Senamile Lale Ngema, et al.
Published: (2023-12-01)

Single Turnover of Transient of Reactants Supports a Complex Interplay of Conformational States in the Mode of Action of <i>Mycobacterium tuberculosis</i> Enoyl Reductase
by: Leonardo Kras Borges Martinelli, et al.
Published: (2023-03-01)

Isoniazid resistance profile in rifampicin resistant Mycobacterium tuberculosis
by: Naomee Shareef, et al.
Published: (2023-09-01)

Contribution of katG, ahpC and inhA mutations to the detection of isoniazid-resistant Mycobacterium tuberculosis isolates from Lebanon and Syria
by: F Dabboussi, et al.
Published: (2015-01-01)

Mutations of rpoB, katG, inhA and ahp genes in rifampicin and isoniazid-resistant Mycobacterium tuberculosis in Kyrgyz Republic
by: Jainagul Isakova, et al.
Published: (2018-03-01)

Design and Synthesis of Highly Active Antimycobacterial Mutual Esters of 2-(2-Isonicotinoylhydrazineylidene)propanoic Acid
by: Václav Pflégr, et al.
Published: (2021-12-01)

Redox Imbalance and Oxidative DNA Damage During Isoniazid Treatment of HIV-Associated Tuberculosis: A Clinical and Translational Pharmacokinetic Study
by: Isaac Zentner, et al.
Published: (2020-07-01)

In vitro anti-mycobacterial activity of (E)-N´-(monosubstituted-benzylidene) isonicotinohydrazide derivatives against isoniazid-resistant strains
by: Tatiane S. Coelho, et al.
Published: (2012-02-01)

Synthesis, Biological Evaluation and Computational Studies of New Hydrazide Derivatives Containing 1,3,4-Oxadiazole as Antitubercular Agents
by: Daniele Zampieri, et al.
Published: (2022-12-01)

Insilico Analysis of Phytoconstituents from Allium sativum as Potential Inhibitors of Inha in Mycobacterium tuberculosis
by: Rmaraj Kannan, et al.

Pattern of InhA and KatG mutations in isoniazid monoresistant Mycobacterium tuberculosis isolates
by: Ashok Singh Charan, et al.
Published: (2020-01-01)

Identification and validation of the mode of action of the chalcone anti-mycobacterial compounds
by: B. Anagani, et al.
Published: (2020-12-01)

Isoniazid Linked to Sulfonate Esters via Hydrazone Functionality: Design, Synthesis, and Evaluation of Antitubercular Activity
by: Ebru Koçak Aslan, et al.
Published: (2022-10-01)

Detection of genetic mutations in inh A and kat G for isoniazid and its association with rifampicin resistance in tuberculosis confirmed by line probe assay: Its rationality for isoniazid prophylaxis empirical or drug susceptibility testing guided
by: Prasanta Kumar Das, et al.
Published: (2019-01-01)

Identification of Novel Inhibitor of Enoyl-Acyl Carrier Protein Reductase (InhA) Enzyme in <i>Mycobacterium tuberculosis</i> from Plant-Derived Metabolites: An In Silico Study
by: Kratika Singh, et al.
Published: (2022-08-01)

New InhA Inhibitors Based on Expanded Triclosan and <i>Di</i>-Triclosan Analogues to Develop a New Treatment for Tuberculosis
by: Sarentha Chetty, et al.
Published: (2021-04-01)

Study of mechanism of interaction of truncated isoniazid–nicotinamide adenine dinucleotide adduct against multiple enzymes of Mycobacterium tuberculosis by a computational approach
by: Lingaraja Jena, et al.
Published: (2015-01-01)

ISONIAZID - MONORESISTANT TUBERCULOSIS IN BULGARIA
by: Stanislava Yordanova, et al.
Published: (2020-05-01)

Recent Advances in Anti-Tuberculosis Drug Discovery Based on Hydrazide–Hydrazone and Thiadiazole Derivatives Targeting InhA
by: Yoanna Teneva, et al.
Published: (2023-03-01)

N-[2-(1H-Indol-3-yl)-1-(5-thioxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)ethyl]-4-methylbenzenesulfonamide
by: Nikil Purushotham, et al.
Published: (2018-07-01)

Effective pragmatic approach of diagnosis of multidrug-resistant tuberculosis by high-resolution melt curve assay
by: Sanjay Singh Negi, et al.
Published: (2018-01-01)

Target Identification of Mycobacterium tuberculosis Phenotypic Hits Using a Concerted Chemogenomic, Biophysical, and Structural Approach
by: Grace Mugumbate, et al.
Published: (2017-09-01)

Karakteristik Morfologi Mycobacterium tuberculosis yang Terpapar Obat Anti TB Isoniazid (INH) secara Morfologi
by: Widodo Widodo, et al.
Published: (2017-08-01)

Treatment outcomes for isoniazid-resistant tuberculosis under program conditions in British Columbia, Canada
by: Kamila Romanowski, et al.
Published: (2017-09-01)

Structural homology between 11 beta-hydroxysteroid dehydrogenase and Mycobacterium tuberculosis Inh-A enzyme: Dehydroepiandrosterone as a potential co-adjuvant treatment in diabetes-tuberculosis comorbidity
by: Israel Hernández-Bustamante, et al.
Published: (2023-01-01)

Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor
by: María Martínez-Hoyos, et al.
Published: (2016-06-01)

Treatment of Isoniazid-Resistant Pulmonary Tuberculosis
by: Byung Woo Jhun, M.D., et al.
Published: (2020-01-01)

Profile of drug-resistant-conferring mutations among new and previously treated pulmonary tuberculosis cases from Aligarh region of Northern India
by: Shariq Ahmed, et al.
Published: (2018-01-01)

Isoniazid, The Frontline of Resistance in Mycobacterium tuberculosis
by: James B. Whitney, et al.
Published: (2002-12-01)

Novel Hybrid 1,2,4- and 1,2,3-Triazoles Targeting Mycobacterium Tuberculosis Enoyl Acyl Carrier Protein Reductase (InhA): Design, Synthesis, and Molecular Docking
by: Maged A. El Sawy, et al.
Published: (2022-04-01)

A bioactive implant combining isoniazid with nanohydroxyapatite/polyamide 66 for the treatment of osteoarticular tuberculosis
by: Tianhang Xie, et al.
Published: (2021-11-01)

Correlation between GenoType MTBDRplus Assay and Phenotypic Susceptibility Test for Prothionamide in Patients with Genotypic Isoniazid Resistance
by: Joo Hee Lee, M.D., et al.
Published: (2019-04-01)

Molecular characterization of Mycobacterium tuberculosis strains resistant to isoniazid
by: Salma Smaoui, et al.
Published: (2016-01-01)

Complication of Mycobacterium tuberculosis treatment: Isoniazid-induced pneumonitis
by: Brian Cody Adkinson, et al.
Published: (2020-11-01)

Protective Effect of Ghrelin on Isoniazid-induced Liver Injury in Rat
by: Kheyabany, Shadi Sar Kheyr, et al.
Published: (2013-02-01)

CURRENT APPROACHES TO CONTROL OF ISONIAZID-RESISTANT TUBERCULOSIS
by: Vladimir Milanov, et al.
Published: (2022-10-01)

Fast test for assessing the susceptibility of Mycobacterium tuberculosis to isoniazid and rifampin by real-time PCR
by: Maria Gisele Gonçalves, et al.
Published: (2012-11-01)